436 related articles for article (PubMed ID: 21788559)
1. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure.
Prébet T; Gore SD; Esterni B; Gardin C; Itzykson R; Thepot S; Dreyfus F; Rauzy OB; Recher C; Adès L; Quesnel B; Beach CL; Fenaux P; Vey N
J Clin Oncol; 2011 Aug; 29(24):3322-7. PubMed ID: 21788559
[TBL] [Abstract][Full Text] [Related]
2. Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes.
Papadopoulos V; Diamantopoulos PT; Papageorgiou SG; Papoutselis M; Vrachiolias G; Pappa V; Galanopoulos AG; Vassilakopoulos TP; Hatzimichael E; Zikos P; Papadaki HA; Bouchla A; Panayiotidis P; Megalakaki A; Papaioannou M; Liapis K; Dryllis G; Tsokanas D; Kourakli A; Symeonidis A; Viniou NA; Kotsianidis I
Hematol Oncol; 2020 Oct; 38(4):541-553. PubMed ID: 32495951
[TBL] [Abstract][Full Text] [Related]
3. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies.
Damaj G; Duhamel A; Robin M; Beguin Y; Michallet M; Mohty M; Vigouroux S; Bories P; Garnier A; El Cheikh J; Bulabois CE; Huynh A; Bay JO; Legrand F; Deconinck E; Fegueux N; Clement L; Dauriac C; Maillard N; Cornillon J; Ades L; Guillerm G; Schmidt-Tanguy A; Marjanovic Z; Park S; Rubio MT; Marolleau JP; Garnier F; Fenaux I; Yakoub-Agha I
J Clin Oncol; 2012 Dec; 30(36):4533-40. PubMed ID: 23109707
[TBL] [Abstract][Full Text] [Related]
4. No clear survival benefit of azacitidine for lower-risk myelodysplastic syndromes: A retrospective study of Nagasaki.
Toriyama E; Hata T; Yokota KI; Chiwata M; Kamijo R; Hashimoto M; Taguchi M; Horai M; Matsuo M; Matsuo E; Takasaki Y; Kawaguchi Y; Itonaga H; Sato S; Ando K; Sawayama Y; Taguchi J; Imaizumi Y; Tsushima H; Jo T; Yoshida S; Moriuchi Y; Miyazaki Y
Cancer Sci; 2020 Dec; 111(12):4490-4499. PubMed ID: 32939867
[TBL] [Abstract][Full Text] [Related]
5. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
[TBL] [Abstract][Full Text] [Related]
6. Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications.
Pleyer L; Burgstaller S; Stauder R; Girschikofsky M; Sill H; Schlick K; Thaler J; Halter B; Machherndl-Spandl S; Zebisch A; Pichler A; Pfeilstöcker M; Autzinger EM; Lang A; Geissler K; Voskova D; Geissler D; Sperr WR; Hojas S; Rogulj IM; Andel J; Greil R
J Hematol Oncol; 2016 Apr; 9():39. PubMed ID: 27084507
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.
Itzykson R; Thépot S; Quesnel B; Dreyfus F; Beyne-Rauzy O; Turlure P; Vey N; Recher C; Dartigeas C; Legros L; Delaunay J; Salanoubat C; Visanica S; Stamatoullas A; Isnard F; Marfaing-Koka A; de Botton S; Chelghoum Y; Taksin AL; Plantier I; Ame S; Boehrer S; Gardin C; Beach CL; Adès L; Fenaux P;
Blood; 2011 Jan; 117(2):403-11. PubMed ID: 20940414
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of a 5-day regimen of azacitidine for patients with high-risk myelodysplastic syndromes.
Fujimaki K; Miyashita K; Kawasaki R; Tomita N
Eur J Haematol; 2016 Sep; 97(3):228-31. PubMed ID: 26613362
[TBL] [Abstract][Full Text] [Related]
9. Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine.
Bouchla A; Thomopoulos TP; Papageorgiou SG; Apostolopoulou C; Loucari C; Mpazani E; Pappa V
Epigenomics; 2021 Jul; 13(14):1129-1143. PubMed ID: 34291653
[TBL] [Abstract][Full Text] [Related]
10. Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes.
Xicoy B; Jiménez MJ; García O; Bargay J; Martínez-Robles V; Brunet S; Arilla MJ; Pérez de Oteyza J; Andreu R; Casaño FJ; Cervero CJ; Bailén A; Díez M; González B; Vicente AI; Pedro C; Bernal T; Luño E; Cedena MT; Palomera L; Simiele A; Calvo JM; Marco V; Gómez E; Gómez M; Gallardo D; Muñoz J; de Paz R; Grau J; Ribera JM; Benlloch LE; Sanz G
Leuk Lymphoma; 2014 Jun; 55(6):1300-3. PubMed ID: 23952246
[TBL] [Abstract][Full Text] [Related]
11. Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial.
Miyazaki Y; Kiguchi T; Sato S; Usuki K; Ishiyama K; Ito Y; Suzuki T; Taguchi J; Chiba S; Dobashi N; Tomita A; Harada H; Handa H; Horiike S; Maeda T; Matsuda M; Ichikawa M; Hata T; Honda S; Iyama S; Suzushima H; Moriuchi Y; Kurokawa T; Yokota K; Ohtake S; Yamauchi T; Matsumura I; Kiyoi H; Naoe T;
Int J Hematol; 2022 Aug; 116(2):228-238. PubMed ID: 35508695
[TBL] [Abstract][Full Text] [Related]
12. Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure.
Duong VH; Lin K; Reljic T; Kumar A; Al Ali NH; Lancet JE; List AF; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):711-5. PubMed ID: 24054159
[TBL] [Abstract][Full Text] [Related]
13. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.
Silverman LR; Demakos EP; Peterson BL; Kornblith AB; Holland JC; Odchimar-Reissig R; Stone RM; Nelson D; Powell BL; DeCastro CM; Ellerton J; Larson RA; Schiffer CA; Holland JF
J Clin Oncol; 2002 May; 20(10):2429-40. PubMed ID: 12011120
[TBL] [Abstract][Full Text] [Related]
14. Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes.
Seymour JF; Fenaux P; Silverman LR; Mufti GJ; Hellström-Lindberg E; Santini V; List AF; Gore SD; Backstrom J; McKenzie D; Beach CL
Crit Rev Oncol Hematol; 2010 Dec; 76(3):218-27. PubMed ID: 20451404
[TBL] [Abstract][Full Text] [Related]
15. Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine.
Jabbour E; Kantarjian H; O'Brien S; Kadia T; Malik A; Welch MA; Teng A; Cortes J; Ravandi F; Garcia-Manero G
Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):592-6. PubMed ID: 23790798
[TBL] [Abstract][Full Text] [Related]
16. Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS.
Zeidan AM; Lee JW; Prebet T; Greenberg P; Sun Z; Juckett M; Smith MR; Paietta E; Gabrilove J; Erba HP; Katterling RP; Tallman MS; Gore SD
Br J Haematol; 2014 Oct; 167(1):62-8. PubMed ID: 24995683
[TBL] [Abstract][Full Text] [Related]
17. [Decitabine treatment in myelodysplastic syndromes--results of a compassionate patient program in Israel].
Klepfish A; Silbershatz I; Lugassy G; Shimoni A; Mittelman M
Harefuah; 2013 Oct; 152(10):591-4, 624. PubMed ID: 24450031
[TBL] [Abstract][Full Text] [Related]
18. Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment.
Calleja A; Yun S; Moreilhon C; Karsenti JM; Gastaud L; Mannone L; Komrokji R; Al Ali N; Dadone-Montaudie B; Robert G; Auberger P; Raynaud S; Sallman DA; Cluzeau T
Eur J Haematol; 2020 May; 104(5):488-498. PubMed ID: 31990086
[TBL] [Abstract][Full Text] [Related]
19. Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine.
Sébert M; Komrokji RS; Sekeres MA; Prebet T; Cluzeau T; Santini V; Gyan E; Sanna A; Ali NH; Hobson S; Eclache V; List A; Fenaux P; Adès L
Leuk Res; 2017 Dec; 63():72-77. PubMed ID: 29112938
[TBL] [Abstract][Full Text] [Related]
20. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes.
Zeidan AM; Davidoff AJ; Long JB; Hu X; Wang R; Ma X; Gross CP; Abel GA; Huntington SF; Podoltsev NA; Hajime U; Prebet T; Gore SD
Br J Haematol; 2016 Dec; 175(5):829-840. PubMed ID: 27650975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
